CERo Therapeutics
CERO----
CERo Therapeutics (CERO)
CERo Therapeutics Holdings, Inc., an immunotherapy company, engages in the development of engineered T cell therapeutics for the treatment of cancer. The compan...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
CERo Therapeutics Analyst Rating
View MoreForecast & Rating
Apr 7, 2026Price forecast
$30.00299900.00%
Forecast & RatingHold
1analysts
- Strong buy0.00%
- Buy0.00%
- Hold100.00%
- Sell0.00%
- Strong sell0.00%
News
- TradingView · Jul 17 at 03:43 PM
Cero Therapeutics Secures $2.09M 10% Convertible Note With SRX Global, Maturing May 2027
- StockTitan · Jul 10 at 03:00 AM
Delisting of Securities from The Nasdaq Stock Market | NDAQ Stock News
- PUBT · Jun 26 at 03:06 PM
Cero Therapeutics amends SRX Health promissory note, lifts borrowing capacity to $1.41 million
- Unusual Whales · Jun 15 at 07:16 AM
CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment
- StockTitan · May 10 at 11:15 PM
CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial | CERO Stock News
- Earnings Watch · Apr 15 at 03:10 PM
CERo Therapeutics | 10-K: FY2025 Revenue: USD 0
